AMIKACIN
THERAPY
OF
EXACERBATIONS
OF
PSEUDOMONAS
AERUGINOSA
INFECTIONS
IN
PATIENTS
WITH
CYSTIC
FIBROSIS
AMIKACIN
A
NEW
SEMISYNTHETIC
AMINOGLYCOSIDE
ANTIBIOTIC
WITH
ACTIVITY
AGAINST
PSEUDOMONAS
AERUGINOSA
WAS
USED
TO
TREAT
22
ACUTE
EXACERBATIONS
OF
CHRONIC
PULMONARY
INFECTIONS
IN
18
PATIENTS
WITH
CYSTIC
FIBROSIS
PATIENTS
RANGED
FROM
5
TO
32
YEARS
OF
AGE
AND
HAD
MUCOID
P
AERUGINOSA
ISOLATED
FROM
SPUTUM
THE
AMIKACIN
DOSE
WAS
USUALLY
75
MGKG
EVERY
EIGHT
HOURS
BUT
WAS
INCREASED
TO
10
MGKG
ANDOR
CARBENICILLIN
WAS
ADDED
IN
SELECTED
CASES
DEPENDING
ON
CLINICAL
COURSE
ALTHOUGH
P
AERUGINOSA
WAS
NOT
ELIMINATED
FROM
OUR
PATIENTS
SPUTUM
EXCEPT
IN
TWO
CASES
THERE
WAS
A
GOOD
CLINICAL
RESPONSE
IN
19
OF
22
COURSES
SIGNIFICANT
IMPROVEMENT
IN
CHEST
XRAY
FILMS
SPIROMETRY
OR
ARTERIAL
OXYGEN
TENSION
WAS
DOCUMENTED
IN
11
OF
17
COURSES
ONE
INSTANCE
OF
SERUM
CREATININE
LEVEL
ELEVATION
COULD
NOT
BE
ATTRIBUTED
TO
THIS
ANTIBIOTIC
TWO
PATIENTS
SHOWED
MINIMAL
15
DB
UNILATERAL
HIGHFREQUENCY
HEARING
LOSS
ON
SERIAL
AUDIOGRAMS
ACTIVITY
AGAINST
MANY
GENTAMICINRESISTANT
STRAINS
AND
HIGH
BLOOD
LEVELS
ARE
AMONG
THE
ATTRACTIVE
PROPERTIES
OF
AMIKACIN
AMIKACIN
IS
CLINICALLY
EFFECTIVE
IN
TREATING
PSEUDOMONASASSOCIATED
PULMONARY
INFECTIONS
COMPLICATING
CYSTIC
FIBROSIS
